Journal of Neuroinflammation · 2009 · 34 citations · 42 references
MedicineNeurobiologyNeuroscienceCellular NeuroscienceNeuroimmunologyNeuropharmacologyGlial Response To InjuryMicroglia BiologyNeuroinflammationNeuronal Cell DeathNeuroprotectionNeuroprotective PharmacologyExcitotoxicity InhibitionGlial-mediated NeurotoxicityMicroglia ModulationMicroglial Responses To InjuryNeuroprotective AgentsNeuroprotective SignalingProstanoid Signaling
BACKGROUND: The EP1 receptor for the prostanoid PGE2 is a G-protein coupled receptor that has been shown to contribute to excitotoxic neuronal death. In this study we examined the influence of non-neuronal cells on neuroprotective properties of EP1 receptor antagonists (Ono 8711 and SC 51089). METHODS: Primary neuronal cultures systems with or without non-neuronal cells were used to examine how the neuroprotective properties of EP1 antagonists were influenced by non-neuronal cells. The influence of astrocytes or microglia were individually tested in excitotoxicity assays using a co-culture system with these cells grown on permeable transwell inserts above the neuronal-enriched cultures. The influence of microglia on PGE2 synthesis and EP1 receptor expression was examined. RESULTS: EP1 antagonists were neuroprotective in neuronal-enriched cultures (> 90% neurons) but not in mixed cultures (30% neurons plus other non-neuronal cells). Co-cultures of microglia on permeable transwell inserts above neuronal-enriched cultures blocked neuroprotection by EP1 antagonists. Incubation of microglia with neuronal-enriched cultures for 48 hours prior to NMDA challenge was sufficient to block neuroprotection by EP1 antagonists. The loss of neuroprotection by EP1 antagonists was accompanied by a decrease of neuronal EP1 expression in the nucleus in cultures with microglia present. CONCLUSION: These findings demonstrate microglial modulation of neuronal excitotoxicity through interaction with the EP1 receptor and may have important implications in vivo where microglia are associated with neuronal injury.
42
Coxibs and Cardiovascular Disease
Garret A. FitzGerald · New England Journal of Medicine · 2004 · 896 citations
Failing the Public Health — Rofecoxib, Merck, and the FDA
Eric J. Topol · New England Journal of Medicine · 2004 · 598 citations · Full text
Imatinib mesylate blocks a non‐Smad TGF‐β pathway and reduces renal fibrogenesis in vivo
Shinong Wang, Mark C. Wilkes, Edward B. Leof et al. · The FASEB Journal · 2005 · 462 citations
Medicine, Nephrology, Pathology +17
Costantino Iadecola, Kiyoshi Niwa, Shigeru Nogawa et al. · Proceedings of the National Academy of Sciences · 2001 · 413 citations · Full text